Recruiting

Observational Study

Sponsor:

UCLA

Code:

NCT04362150

Conditions

COVID

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.

Conditions

COVID

Study ID

NCT04362150

Start date

Apr 21, 2020

Status verified date

Jul, 2026

Completion date

Dec 31, 2030

Anticipated

Primary completion date

Dec 31, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Willing and able to provide written informed consent, and
2. Age >/= 18 years, and
3. A history of SARS-CoV-2 infection, as evidenced by:

1. Available laboratory documentation of SARS-CoV-2 RNA positivity on a nucleic acid amplification test or by serologic testing when this becomes available, or
2. Reference by the participant to a laboratory test performed on respiratory tract secretions or blood, fingerstick, or saliva test that was reported to the participant to be positive for SARS-CoV-2 or COVID-19 infection,
4. And a period of 21 days or more has elapsed since the first positive test or symptoms preceding the first positive test, whichever is earlier.

Exclusion Criteria:

1. Self-reported or documented chronic anemia with hemoglobin < 9 g/dL. Anemia during a preceding acute illness will not be exclusionary.
2. Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent.
3. Active drug or alcohol use or dependence that, in the opinion of the Principal Investigator, would interfere with adherence to study requirements or to give informed consent.

Study Design

Enrollment

800 participants

Anticipated

Interventions and Outcome Measures

Arms

COVID-19 positive, recovered

Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).

Primary outcome measure

  • Participant age [ Time Frame: Baseline visit ]
  • Participant sex [ Time Frame: Baseline visit ]
  • Participant race/ethnicity [ Time Frame: Baseline visit ]
  • Proportion of participants previously hospitalized. [ Time Frame: Baseline visit ]

Central Contacts and Locations

Central contacts

Locations

Zuckerberg San Francisco General Hospital (ZSFG)

Recruiting

San Francisco, California, United States, 94110

Contacts

Principal Investigator:

Steven G Deeks, MD

More Information

Sponsor

University of California, San Francisco

Last update posted

Jul 23, 2026

Last verified

Jul, 2026

Keywords

  • COVID-19
  • coronavirus
  • SARS-CoV-2
  • Long COVID
  • post-acute sequelae of SARS-CoV-2

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-07-23.